These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 25387808)

  • 1. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
    Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
    Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
    Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
    Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.
    Zhou M; Yu P; Qu X; Liu Y; Zhang J
    PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Li Q; Yan H; Zhao P; Yang Y; Cao B
    Sci Rep; 2015 Oct; 5():15746. PubMed ID: 26503902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
    Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
    Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
    Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
    Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.
    Wang X; Huang C; Li M; Gu Y; Cui Y; Li Y
    Tumour Biol; 2014 May; 35(5):4841-8. PubMed ID: 24570182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
    Lück HJ; Lübbe K; Reinisch M; Maass N; Feisel-Schwickardi G; Tomé O; Janni W; Aydogdu M; Neunhöffer T; Ober A; Aktas B; Park-Simon TW; Schumacher C; Höffkes HG; Illmer T; Wagner H; Mehta K; von Minckwitz G; Nekljudova V; Loibl S
    Breast Cancer Res Treat; 2015 Jan; 149(1):141-9. PubMed ID: 25519041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.
    Croom KF; Dhillon S
    Drugs; 2011 Nov; 71(16):2213-29. PubMed ID: 22035518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
    J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
    Brodowicz T; Lang I; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Petruzelka L; Eniu A; Anghel R; Koynov K; Vrbanec D; Pienkowski T; Melichar B; Spanik S; Ahlers S; Messinger D; Inbar MJ; Zielinski C
    Br J Cancer; 2014 Nov; 111(11):2051-7. PubMed ID: 25268370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis.
    Sun Z; Lan X; Xu S; Li S; Xi Y
    BMC Cancer; 2020 Mar; 20(1):180. PubMed ID: 32131770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
    Cao L; Yao GY; Liu MF; Chen LJ; Hu XL; Ye CS
    PLoS One; 2015; 10(12):e0145442. PubMed ID: 26717149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.